Product Description
To reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in babies born premature (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04662151)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Airway Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Israel, Italy, Spain, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Bronchopulmonary Dysplasia|Lung Injury
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06897839 |
ZELA | P3 |
Active, not recruiting |
Bronchopulmonary Dysplasia |
2027-12-31 |
26% |
2025-09-09 |
|
2024-513420-41-00 |
ZEL-003 | P3 |
Recruiting |
Lung Injury|Bronchopulmonary Dysplasia |
2027-03-01 |
26% |
2025-05-02 |
Treatments |
NCT04662151 |
AT-100/001 | P1 |
Completed |
Bronchopulmonary Dysplasia |
2023-08-14 |
88% |
2024-07-05 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |